News|Articles|March 24, 2005

Warning Letter: Germiphene

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

Midyear 2026 Check-In: AI Investment Skipped Pharma's Costliest Operational Problem

ByMegha Sinha,Zachary Zubulake

July 23rd 2026

FDA Approves GSK’s Jideytro for ROS1-positive Lung Cancer

What Jideytro's Approval Means for Drug Developers

ByZachary Zubulake

July 23rd 2026

Midyear 2026 Check in: Abzena’s Campbell Bunce on Trends in Antibody Drug Conjugates

ByCampbell Bunce,Susan Haigney

July 23rd 2026

Brent Wilhelm, Senior Vice President of Global Supply Chain, Cencora

Brent Wilhelm on Cold Chain Pharmaceuticals Reshaping Shipping Needs

ByBrent Wilhelm,Zachary Zubulake

July 22nd 2026

Midyear 2026 Check-In: Megha Sinha on Pharma's AI Skills Gap

ByMegha Sinha,Zachary Zubulake

July 21st 2026

Warning Letter: Germiphene

Related Content

Midyear 2026 Check-In: AI Investment Skipped Pharma's Costliest Operational Problem

What Jideytro's Approval Means for Drug Developers

Midyear 2026 Check in: Abzena’s Campbell Bunce on Trends in Antibody Drug Conjugates

Brent Wilhelm on Cold Chain Pharmaceuticals Reshaping Shipping Needs

Midyear 2026 Check-In: Megha Sinha on Pharma's AI Skills Gap

Trending on Pharmaceutical Technology

Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads, Alleging Omitted GLP-1 Dosing Data

Brent Wilhelm on Cold Chain Pharmaceuticals Reshaping Shipping Needs

What Jideytro's Approval Means for Drug Developers

Midyear 2026 Check in: Abzena’s Campbell Bunce on Trends in Antibody Drug Conjugates

Ask the Expert: Drug Approval Submissions